Difference between revisions of "POEMS syndrome"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this i...")
 
m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''")
 
(57 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''
+
<span id="BackToTop"></span>
−
 
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
+
[[#top|Back to Top]]
−
 
+
</div>
−
<big>'''POEMS:''' '''<u>P</u>'''eripheral neuropathy, '''<u>O</u>'''rganomegaly, '''<u>E</u>'''ndocrinopathy, '''<u>M</u>'''onoclonal plasma cell disorder, and '''<u>S</u>'''kin changes</big>
+
{{#lst:Editorial board transclusions|pcd}}
 +
'''POEMS:''' '''<u>P</u>'''eripheral neuropathy, '''<u>O</u>'''rganomegaly, '''<u>E</u>'''ndocrinopathy, '''<u>M</u>'''onoclonal plasma cell disorder, and '''<u>S</u>'''kin changes
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
 
+
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 +
==EMN==
 +
*'''2018:''' Gavriatopoulou et al. [https://doi.org/10.1038/s41375-018-0209-7 European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias] [https://pubmed.ncbi.nlm.nih.gov/30038381/ PubMed]
 
=All lines of therapy=
 
=All lines of therapy=
−
 
+
==Lenalidomide & Dexamethasone (Rd) {{#subobject:dc6eae|Regimen=1}}==
−
==RD {{#subobject:dc6eae|Regimen=1}}==
+
Rd: '''<u>R</u>'''evlimid (Lenalidomide) & low-dose '''<u>d</u>'''examethasone
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
RD: '''<u>R</u>'''evlimid (Lenalidomide) & '''<u>D</u>'''examethasone
 
 
===Regimen {{#subobject:be34d7|Variant=1}}===
 
===Regimen {{#subobject:be34d7|Variant=1}}===
−
{| border="1" style="text-align:center;" !align="left"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
|'''Study'''
+
!style="width: 33%"|Study
−
|[[Levels_of_Evidence#Evidence|'''Evidence''']]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.14966/full Nozza et al. 2017]
+
|[https://doi.org/10.1111/bjh.14966 Nozza et al. 2017]
−
|style="background-color:#ff0000"|Phase II, <20 pts
+
|2009-10 to 2014-10
 +
|style="background-color:#ffffbe"|Phase 2, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
−
====Chemotherapy====
+
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Targeted therapy====
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
−
*[[Dexamethasone (Decadron)]] 40 mg PO once per week
+
====Glucocorticoid therapy====
−
 
+
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22
−
====Supportive medications====
+
====Supportive therapy====
 
*[[Aspirin]] 100 mg PO once per day
 
*[[Aspirin]] 100 mg PO once per day
 
**[[:Category:Low_molecular_weight_heparins|LMWH]] in "intolerant" patients
 
**[[:Category:Low_molecular_weight_heparins|LMWH]] in "intolerant" patients
−
*[[Trimethoprim/Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] 800 mg PO BID two days per week
+
*[[Trimethoprim-Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] 800 mg PO twice per day two days per week
−
 
+
'''28-day cycle for at least 6 cycles'''
−
'''Monthly cycles, continued until progression or excess toxicity'''
+
</div></div>
−
 
 
 
===References===
 
===References===
−
# Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.14966/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29048107 PubMed]
+
# Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. [https://doi.org/10.1111/bjh.14966 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29048107/ PubMed] EudraCT 2008-003202-33
−
 
+
[[Category:POEMS syndrome regimens]]
−
[[Category:POEMS regimens]]
 
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Plasma cell dyscrasias]]
 
[[Category:Plasma cell dyscrasias]]

Latest revision as of 12:24, 15 July 2024

Back to Top

Section editor
Samuelrubinstein.jpg
 Samuel M. Rubinstein, MD
University of North Carolina
Chapel Hill, NC, USA
LinkedIn

POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes

1 regimens on this page
1 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

EMN

All lines of therapy

Lenalidomide & Dexamethasone (Rd)

Rd: Revlimid (Lenalidomide) & low-dose dexamethasone

Regimen

Study Dates of enrollment Evidence
Nozza et al. 2017 2009-10 to 2014-10 Phase 2, fewer than 20 pts

Targeted therapy

Glucocorticoid therapy

Supportive therapy

28-day cycle for at least 6 cycles

References

  1. Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed EudraCT 2008-003202-33
Retrieved from "https://hemonc.org/w/index.php?title=POEMS_syndrome&oldid=89655"